Protein Summary
Could act as a modulator of transcription. The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. This gene, and also the SSX2 and SSX4 family members, have been involved in t(X;18)(p11.2;q11.2) translocations that are characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are likely responsible for transforming activity. Alternative splicing of this gene results in multiple transcript variants. A related pseudogene has been identified on chromosome X. [provided by RefSeq, Jul 2013]
- ENST00000376919
- ENSP00000366118
- ENSG00000126752
- SSRC
- CT5.1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
tissue | 0.72 | ||
protein domain | 0.58 | ||
biological process | 0.49 | ||
small molecule perturbation | 0.43 | ||
biological term | 0.42 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 131.71 (req: < 5)
Gene RIFs: 23 (req: <= 3)
Antibodies: 179 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 131.71 (req: >= 5)
Gene RIFs: 23 (req: > 3)
Antibodies: 179 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 3
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0